Review proposal consultation | Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor | Guidance

NICE is considering whether new evidence has emerged that would affect the recommendation of TA909.

This page was last updated: 25 June 2024